Clinical Trials Directory

Trials / Completed

CompletedNCT06362018

Bioavailability of Five Mitopure Formulations

A Comparative Pharmacokinetic Profiles of Five Urolithin A Formulations in Healthy Volunteers: A Randomized, Open-label, Single-dose, Parallel-arm Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Amazentis SA · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study's design as an open-label, single-dose, randomized trial that aligns with the objective of characterizing the concentration-time profiles of five Urolithin A (Mitopure) formulations in a controlled setting. The inclusion criteria, stringent fasting requirements, standardized fluid intake and strict dietary restriction protocols ensure homogeneity among the study participants, enhancing the reliability of the outcomes. Ultimately, this clinical trial aims to contribute valuable insights into the pharmacokinetic behavior of the different Urolithin A formulations, facilitating informed decisions for future developments and applications in the realm of health and wellness.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTMitopure (Urolithin A)Mitopure (Urolithin A) is gut microbiome derived postbiotic that has been shown to improve muscle and mitochondrial health

Timeline

Start date
2024-05-07
Primary completion
2025-03-14
Completion
2025-03-14
First posted
2024-04-12
Last updated
2025-04-10

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT06362018. Inclusion in this directory is not an endorsement.

Bioavailability of Five Mitopure Formulations (NCT06362018) · Clinical Trials Directory